Abstract
Asthma is a chronic disease of the airways affecting around 10% of the population. The majority of cases are well controlled with current therapies, however in approximately 20% of severe asthmatics the available therapeutic strategies are inadequate. Structural changes in the asthmatic airway, including an increase in smooth muscle mass and an increased deposition of extracellular matrix proteins, which correlate with airway hyperresponsivenes, reduced lung function and an increase in fibroblast/myofibroblast numbers, are not specifically targetted by current therapeutic agents and therefore represent an area of unmet need. The mechanisms involved in the development of airway remodelling are incompletely understood but are thought to involve one or more isoforms of transforming growth factor-β (TGF-β). The TGF-βs are pleiotropic mediators which have important roles in the regulation of inflammation, cell growth, differentiation and wound healing. All three mammalian isoforms of TGF-b are present in the airways and at least TGF-β1 and TGF- β2 have been shown to be increased in asthmatic airways and cells, together with evidence of increased TGF-β signalling. In addition, evidence from animal models suggests that airway remodelling may be prevented or reversed using agents which target TGF-β. Therefore modulation of TGF-βs or their activity represent a potential therapeutic target for asthma. This review focuses on the current knowledge of TGF-β1-3, their their role in normal and asthmatic airways, as well as the potential for modulating the TGF-βs and their effects as a therapeutic approach to asthma.
Keywords: TGF-β, asthma, drug target, remodelling, airways
Current Drug Targets
Title: TGF-β: Its Role in Asthma and Therapeutic Potential
Volume: 7 Issue: 5
Author(s): Jane E. Howell and Robin J. McAnulty
Affiliation:
Keywords: TGF-β, asthma, drug target, remodelling, airways
Abstract: Asthma is a chronic disease of the airways affecting around 10% of the population. The majority of cases are well controlled with current therapies, however in approximately 20% of severe asthmatics the available therapeutic strategies are inadequate. Structural changes in the asthmatic airway, including an increase in smooth muscle mass and an increased deposition of extracellular matrix proteins, which correlate with airway hyperresponsivenes, reduced lung function and an increase in fibroblast/myofibroblast numbers, are not specifically targetted by current therapeutic agents and therefore represent an area of unmet need. The mechanisms involved in the development of airway remodelling are incompletely understood but are thought to involve one or more isoforms of transforming growth factor-β (TGF-β). The TGF-βs are pleiotropic mediators which have important roles in the regulation of inflammation, cell growth, differentiation and wound healing. All three mammalian isoforms of TGF-b are present in the airways and at least TGF-β1 and TGF- β2 have been shown to be increased in asthmatic airways and cells, together with evidence of increased TGF-β signalling. In addition, evidence from animal models suggests that airway remodelling may be prevented or reversed using agents which target TGF-β. Therefore modulation of TGF-βs or their activity represent a potential therapeutic target for asthma. This review focuses on the current knowledge of TGF-β1-3, their their role in normal and asthmatic airways, as well as the potential for modulating the TGF-βs and their effects as a therapeutic approach to asthma.
Export Options
About this article
Cite this article as:
Howell E. Jane and McAnulty J. Robin, TGF-β: Its Role in Asthma and Therapeutic Potential, Current Drug Targets 2006; 7 (5) . https://dx.doi.org/10.2174/138945006776818692
DOI https://dx.doi.org/10.2174/138945006776818692 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inventions Designed to Enhance Drug Delivery Across Epithelial and Endothelial Cells Through the Paracellular Pathway
Recent Patents on Drug Delivery & Formulation Current and Experimental Antibody-Based Therapeutics: Insights, Breakthroughs, Setbacks and Future Directions
Current Molecular Medicine Recent Advances in Identification and Characterization of β-Adrenoceptor Agonists and Antagonists
Current Topics in Medicinal Chemistry 5-Lipoxygenase: Cellular Biology and Molecular Pharmacology
Current Drug Targets - Inflammation & Allergy Novel Drugs for Inflammatory Lung Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Molecular Mechanisms and Treatment of Radiation-Induced Lung Fibrosis
Current Drug Targets Modified Recombinant Allergens for Safer Immunotherapy
Inflammation & Allergy - Drug Targets (Discontinued) Cytotoxic Effects on B Lymphocytes Mediated by Reactive Oxygen Species
Current Pharmaceutical Design Food Allergy
Current Pharmaceutical Design Thymoquinone Anticancer Discovery: Possible Mechanisms
Current Drug Discovery Technologies Target-oriented Mechanisms of Novel Herbal Therapeutics in the Chemotherapy of Gastrointestinal Cancer and Inflammation
Current Pharmaceutical Design How Recent Patents Have Changed our Clinical Approach in Cardio-Thoracic Surgery
Recent Patents on Regenerative Medicine Immediate and Late Adverse Reactions to Iodinated Contrast Media: A Pharmacological Point of View
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets Tackling Chronic Pain and Inflammation through the Purinergic System
Current Medicinal Chemistry Study of SARS-nCoV2 Indian Isolates Gaining Insights into Mutation Frequencies, Protein Stability and Prospective Effect on Pathogenicity
Coronaviruses Controlled Parenteral Formulations: An Efficacious and Favourable Way to Deliver the Anti-psychotic Drugs
Current Psychiatry Research and Reviews Preface [Hot Topic: Novel Immunomodulatory Effects of Macrolides in Inflammatory Lung Disease (Executive Editors: F. Martinez and T.J. Standiford)]
Current Pharmaceutical Design Recent Advances on the Roles of NO in Cancer and Chronic Inflammatory Disorders
Current Medicinal Chemistry Airway Smooth Muscle Phenotype and Function: Interactions with Current Asthma Therapies
Current Drug Targets